A Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a biotechnology company based in Barcelona, Spain, has secured $87 million in funding to develop next-generation Antibody-Drug Conjugates (ADCs). The company aims to create differentiated treatments for advanced breast and colorectal cancers to aid patient outcomes.
biotech funding anticancer drugs ADCs Barcelona